Published in Br J Clin Pharmacol on February 12, 2007
Clinical pharmacology--providing tools and expertise for translational medicine. Br J Clin Pharmacol (2008) 1.19
Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects. Hum Genomics (2009) 1.06
A systems approach to designing effective clinical trials using simulations. Circulation (2012) 0.89
Assessment of inter-individual variability in predicted phenytoin clearance. Eur J Clin Pharmacol (2009) 0.81
CYP2B6 pharmacogenetics-based in vitro-in vivo extrapolation of efavirenz clearance by physiologically based pharmacokinetic modeling. Drug Metab Dispos (2013) 0.80
Application of in vitro-in vivo extrapolation (IVIVE) and physiologically based pharmacokinetic (PBPK) modelling to investigate the impact of the CYP2C8 polymorphism on rosiglitazone exposure. Eur J Clin Pharmacol (2013) 0.76
Mechanism-based pharmacokinetic modeling to evaluate transporter-enzyme interplay in drug interactions and pharmacogenetics of glyburide. AAPS J (2014) 0.76
More Power to OATP1B1: An Evaluation of Sample Size in Pharmacogenetic Studies Using a Rosuvastatin PBPK Model for Intestinal, Hepatic, and Renal Transporter-Mediated Clearances. J Clin Pharmacol (2016) 0.75
Prediction of creatinine clearance from serum creatinine. Nephron (1976) 64.02
Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther (1975) 7.96
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet (1999) 7.39
Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA (2002) 5.26
The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood (2005) 4.91
A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood (2004) 4.70
Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos (1999) 3.07
Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther (2006) 3.06
The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics (1996) 3.02
Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics (2002) 2.83
Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics (1994) 2.32
Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin. Thromb Haemost (2006) 2.22
VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. Clin Pharmacol Ther (2006) 2.19
Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther (2002) 2.08
Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci (2005) 1.95
Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther (2007) 1.90
Clinical pharmacokinetics and pharmacodynamics of warfarin. Understanding the dose-effect relationship. Clin Pharmacokinet (1987) 1.84
Interindividual variability in sensitivity to warfarin--Nature or nurture? Clin Pharmacol Ther (2001) 1.77
Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype. Pharmacogenetics (2004) 1.75
Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood (2000) 1.73
Genetic modulation of oral anticoagulation with warfarin. Thromb Haemost (2000) 1.67
Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin Pharmacol Ther (1974) 1.61
Kinetics of pharmacologic effects in man: the anticoagulant action of warfarin. Clin Pharmacol Ther (1969) 1.50
Prediction of pharmacokinetics prior to in vivo studies. II. Generic physiologically based pharmacokinetic models of drug disposition. J Pharm Sci (2002) 1.44
CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics (2000) 1.43
Changes in liver volume from birth to adulthood: a meta-analysis. Liver Transpl (2005) 1.41
Studies on the optical enantiomorphs of warfarin in man. Clin Pharmacol Ther (1974) 1.40
CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy. Clin Pharmacol Ther (2004) 1.40
Several-fold increase in risk of overanticoagulation by CYP2C9 mutations. Clin Pharmacol Ther (2005) 1.35
Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther (2004) 1.31
Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes. Pharmacogenetics (1998) 1.24
Prediction of in vivo drug clearance from in vitro data. I: impact of inter-individual variability. Xenobiotica (2006) 1.24
Stereochemical aspects of warfarin drug interactions: use of a combined pharmacokinetic-pharmacodynamic model. Clin Pharmacol Ther (1994) 1.21
Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. Pharmacogenetics (2004) 1.14
Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. Biochem Pharmacol (1998) 1.13
Towards a mechanism-based analysis of pharmacodynamic drug-drug interactions in vivo. Pharmacol Ther (2004) 1.12
Warfarin dosing and cytochrome P450 2C9 polymorphisms. Thromb Haemost (2004) 1.12
Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver. Br J Clin Pharmacol (2003) 1.11
Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin Pharmacol Ther (2003) 1.10
Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors. Xenobiotica (2004) 1.05
The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin. J Am Coll Surg (2002) 1.00
More efficient clinical trials through use of scientific model-based statistical tests. Clin Pharmacol Ther (2002) 0.96
Dietary vitamin K influences intra-individual variability in anticoagulant response to warfarin. Br J Haematol (2004) 0.92
Pharmacokinetic interaction between warfarin and a uricosuric agent, bucolome: application of In vitro approaches to predicting In vivo reduction of (S)-warfarin clearance. Drug Metab Dispos (1999) 0.84
[Cytochrome P450 2C9 polymorphisms (CYP2C9) and warfarin maintenance dose in elderly patients]. Rev Med Interne (2004) 0.81
Incorporating in vitro information on drug metabolism into clinical trial simulations to assess the effect of CYP2D6 polymorphism on pharmacokinetics and pharmacodynamics: dextromethorphan as a model application. J Clin Pharmacol (2007) 0.80
Enhanced standardization of the International Normalized Ratio through the use of plasma calibrants: a concise review. Blood Coagul Fibrinolysis (2000) 0.79
Differences in cytochrome p450-mediated pharmacokinetics between chinese and caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling. Clin Pharmacokinet (2013) 2.22
Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos (2002) 1.92
The Simcyp population-based ADME simulator. Expert Opin Drug Metab Toxicol (2009) 1.88
Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet (2006) 1.69
Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat Rev Drug Discov (2007) 1.63
Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol (2004) 1.61
Modified-release hydrocortisone to provide circadian cortisol profiles. J Clin Endocrinol Metab (2009) 1.57
A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recognition of covariates. Drug Metab Pharmacokinet (2009) 1.56
Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance. Clin Pharmacokinet (2011) 1.55
Changes in liver volume from birth to adulthood: a meta-analysis. Liver Transpl (2005) 1.41
Population-based mechanistic prediction of oral drug absorption. AAPS J (2009) 1.38
Anatomical, physiological and metabolic changes with gestational age during normal pregnancy: a database for parameters required in physiologically based pharmacokinetic modelling. Clin Pharmacokinet (2012) 1.36
A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin Pharmacokinet (2010) 1.34
Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice. Paediatr Anaesth (2011) 1.31
Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency. Clin Endocrinol (Oxf) (2004) 1.22
Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr Drug Metab (2007) 1.22
Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. Curr Drug Metab (2008) 1.22
Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer (2005) 1.16
Prediction of Voriconazole Non-linear Pharmacokinetics Using a Paediatric Physiologically Based Pharmacokinetic Modelling Approach. Clin Pharmacokinet (2015) 1.09
Prediction of intestinal first-pass drug metabolism. Curr Drug Metab (2007) 1.09
Combining the 'bottom up' and 'top down' approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical data. Br J Clin Pharmacol (2015) 1.06
Changes to methadone clearance during pregnancy. Eur J Clin Pharmacol (2005) 1.03
The effect of ethanol on the release of opioids from oral prolonged-release preparations. Drug Dev Ind Pharm (2007) 1.02
Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA. J Psychopharmacol (2006) 0.99
Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment. Br J Clin Pharmacol (2009) 0.98
A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4. Br J Clin Pharmacol (2012) 0.97
Modeling and predicting drug pharmacokinetics in patients with renal impairment. Expert Rev Clin Pharmacol (2011) 0.97
Age related changes in fractional elimination pathways for drugs: assessing the impact of variable ontogeny on metabolic drug-drug interactions. J Clin Pharmacol (2013) 0.95
Cytochrome P450 3A expression and activity in the human small intestine. Clin Pharmacol Ther (2004) 0.94
The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans. J Clin Psychopharmacol (2008) 0.92
Pharmacometrics in pregnancy: An unmet need. Annu Rev Pharmacol Toxicol (2014) 0.91
A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women. Drug Metab Dispos (2013) 0.91
Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19. Br J Clin Pharmacol (2014) 0.91
Does age affect gastric emptying time? A model-based meta-analysis of data from premature neonates through to adults. Biopharm Drug Dispos (2015) 0.89
Methodologies for investigating drug metabolism at the early drug discovery stage: prediction of hepatic drug clearance and P450 contribution. Curr Drug Metab (2010) 0.89
The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel. Drug Metab Dispos (2011) 0.89
Misuse of the well-stirred model of hepatic drug clearance. Drug Metab Dispos (2007) 0.89
Single-dose pharmacokinetic study of clomiphene citrate isomers in anovular patients with polycystic ovary disease. J Clin Pharmacol (2008) 0.89
Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models. Br J Clin Pharmacol (2011) 0.88
Predicting drug-drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach. Expert Rev Clin Pharmacol (2013) 0.87
Trends in oral drug bioavailability following bariatric surgery: examining the variable extent of impact on exposure of different drug classes. Br J Clin Pharmacol (2012) 0.86
The effects of dose staggering on metabolic drug-drug interactions. Eur J Pharm Sci (2003) 0.86
Metabolism of ethylbenzene by human liver microsomes and recombinant human cytochrome P450s (CYP). Toxicol Lett (2004) 0.85
Simultaneous quantification of the abundance of several cytochrome P450 and uridine 5'-diphospho-glucuronosyltransferase enzymes in human liver microsomes using multiplexed targeted proteomics. Drug Metab Dispos (2014) 0.85
Assessment of in vivo CYP2D6 activity: differential sensitivity of commonly used probes to urine pH. J Clin Pharmacol (2004) 0.85
A mechanistic pharmacokinetic model to assess modified oral drug bioavailability post bariatric surgery in morbidly obese patients: interplay between CYP3A gut wall metabolism, permeability and dissolution. J Pharm Pharmacol (2012) 0.84
A re-evaluation and validation of ontogeny functions for cytochrome P450 1A2 and 3A4 based on in vivo data. Clin Pharmacokinet (2014) 0.84
PRN prescribing in psychiatric inpatients: potential for pharmacokinetic drug interactions. J Psychopharmacol (2007) 0.83
Application of permeability-limited physiologically-based pharmacokinetic models: part I-digoxin pharmacokinetics incorporating P-glycoprotein-mediated efflux. J Pharm Sci (2013) 0.83
Prediction of concentration-time profile and its inter-individual variability following the dermal drug absorption. J Pharm Sci (2012) 0.83
An indirect response model of homocysteine suppression by betaine: optimising the dosage regimen of betaine in homocystinuria. Br J Clin Pharmacol (2002) 0.82
Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model. Xenobiotica (2011) 0.82
Fraction absorbed (Fabs ): different connotations and confusion for the literature? Biopharm Drug Dispos (2011) 0.82
Assessment of inter-individual variability in predicted phenytoin clearance. Eur J Clin Pharmacol (2009) 0.81
Application of permeability-limited physiologically-based pharmacokinetic models: part II - prediction of P-glycoprotein mediated drug-drug interactions with digoxin. J Pharm Sci (2013) 0.81
Incorporation of stochastic variability in mechanistic population pharmacokinetic models: handling the physiological constraints using normal transformations. J Pharmacokinet Pharmacodyn (2015) 0.81
Prediction of plasma protein binding displacement and its implications for quantitative assessment of metabolic drug-drug interactions from in vitro data. J Pharm Sci (2006) 0.81
Modelling and simulation in prediction of human xenobiotic absorption, distribution, metabolism and excretion (ADME): in vitro-in vivo extrapolations (IVIVE). Xenobiotica (2007) 0.81
The generation, detection, and effects of reactive drug metabolites. Med Res Rev (2012) 0.81
Influence of the thr164ile polymorphism in the beta2-adrenoceptor on the effects of beta-adrenoceptor agonists on human lung mast cells. Int Immunopharmacol (2003) 0.80
Evaluation of an existing nomogram for predicting the response to clomiphene citrate. Fertil Steril (2006) 0.80
Incorporating in vitro information on drug metabolism into clinical trial simulations to assess the effect of CYP2D6 polymorphism on pharmacokinetics and pharmacodynamics: dextromethorphan as a model application. J Clin Pharmacol (2007) 0.80
Alternative fusion protein strategies to express recalcitrant QconCAT proteins for quantitative proteomics of human drug metabolizing enzymes and transporters. J Proteome Res (2013) 0.79
The effects of portal shunts on intestinal cytochrome P450 3A activity. Hepatology (2002) 0.79
Pharmacokinetic-pharmacodynamic modeling of mood and withdrawal symptoms in relation to plasma concentrations of methadone in patients undergoing methadone maintenance treatment. J Clin Psychopharmacol (2012) 0.79
Development and Application of a Mechanistic Pharmacokinetic Model for Simvastatin and its Active Metabolite Simvastatin Acid Using an Integrated Population PBPK Approach. Pharm Res (2014) 0.79
CYP2D6 is primarily responsible for the metabolism of clomiphene. Drug Metab Pharmacokinet (2008) 0.79
Protein expression of various hepatic uridine 5'-diphosphate glucuronosyltransferase (UGT) enzymes and their inter-correlations: a meta-analysis. Biopharm Drug Dispos (2014) 0.79
The use of ROC analysis for the qualitative prediction of human oral bioavailability from animal data. Pharm Res (2013) 0.79
Comparison of the rates of disintegration, gastric emptying, and drug absorption following administration of a new and a conventional paracetamol formulation, using gamma scintigraphy. Pharm Res (2003) 0.79